Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2017-05-19 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
监事会关于首次授予限制性股票第三期解锁及预留限制性股票第二期解锁的核查意见
Share Issue/Capital Change Classification · 90% confidence The document is a supervisory board's verification opinion regarding the unlocking of restricted stock awards under a stock incentive plan. It discusses compliance with regulatory requirements and confirms the legitimacy of the unlocking process for specific stock incentive tranches. There is no indication that this is a full financial report, earnings release, or regulatory filing. Instead, it is a formal opinion related to stock incentive plan implementation, which aligns with announcements about share issues or capital changes. Given the content focuses on stock unlocking under an incentive plan, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is short but contains substantive content about stock unlocking, so it is not merely an announcement of a report (RPA) or a regulatory filing (RNS).
2017-05-19 Chinese
第九届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the unlocking of restricted stock under a stock incentive plan. It includes details of the meeting, voting results, and compliance with company law and articles of association. There is no financial data, no mention of annual or quarterly reports, no audit information, no earnings release, and no investor presentation. The content is about a board/committee decision on stock incentive matters, which fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. Therefore, the classification is MANG with high confidence.
2017-05-19 Chinese
第九届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 金宇生物技术股份有限公司 (Jinyu Biotechnology Co., Ltd.). It details voting results on matters related to the company's restricted stock incentive plan, including performance assessments and stock unlocking schedules. The document includes the date of the board meeting, the number of directors voting, and the approval results. There is no financial data, no mention of annual or quarterly reports, no earnings data, no legal proceedings, no merger or acquisition activity, and no shareholder voting results at a general meeting. The content is focused on board decisions and internal management matters related to stock incentives. Therefore, this document fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management.
2017-05-19 Chinese
北京市中伦律师事务所关于金宇生物技术股份有限公司限制性股票激励计划首次授予的限制性股票第三次解锁及预留限制性股票第二次解锁相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the unlocking of restricted stock under a stock incentive plan for a company. It discusses legal compliance, approval procedures, and conditions for unlocking restricted shares. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of a report but a legal opinion related to stock incentive unlocking. This type of document fits best under Regulatory Filings (RNS) as it is a legal compliance document and does not match other specific categories like Capital/Financing Update or Director's Dealing. The document length is 4400 characters, which is relatively short but contains substantive legal content rather than a mere announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2017-05-19 Chinese
股权激励计划首次授予的限制性股票第三期解锁及预留限制性股票第二期解锁暨上市公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the unlocking and listing of restricted shares under a stock incentive plan by the company 金宇生物技术股份有限公司. It includes specifics about the stock incentive plan approval, implementation, unlocking conditions, stock quantities, and legal opinions. The content focuses on the company's equity incentive plan and the unlocking of restricted stock shares, which is a capital structure event related to share issuance and stock unlocking. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a simple announcement of a report publication but a substantive disclosure about stock unlocking and listing. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as restricted stock unlocking and listing.
2017-05-19 Chinese
独立董事关于首次授予限制性股票第三期解锁及预留限制性股票第二期解锁的独立意见
Remuneration Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the unlocking of restricted stock awards under a stock incentive plan. It references compliance with stock incentive regulations and company bylaws, and provides formal approval and legal validation of the unlocking process. There is no financial data, earnings information, or report publication announcement. The content is related to governance and management decisions about stock incentives, which aligns with Remuneration Information filings that detail executive and director compensation plans and related approvals.
2017-05-19 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.